FIELD: organic chemistry, biochemistry, medicine.
SUBSTANCE: invention relates to a new biologically active compound of 4-oxoquinoline that is useful as an anti-HIV agent and to its pharmaceutically acceptable salt. Invention describes an anti-HIV agent comprising compound of 4-oxoquinoline represented by the following formula [I] or its pharmaceutically acceptable salt as an active component wherein ring Cy represents phenyl group, naphthyl group or pyridyl group and each this group is substituted optionally with 1-5 substituted chosen from the following group A wherein A represents the group consisting of cyano-group, phenyl group, nitro-group, halogen atom, (C1-C4)-alkyl group, halogen-(C1-C4)-alkyl group, halogen-(C1-C4)-alkoxy-group, -ORa1, -SRa1, -NRa1Ra2, -CONRa1Ra2, -SO2NRa1Ra2, -NRa1CORa3, -SO2Ra3, -NRa1SO2Ra3 and -COORa1 wherein Ra1 and Ra2 are similar or different and each represents hydrogen atom, (C1-C4)-alkyl group or benzyl group, and Ra3 represents (C1-C4)-alkyl group; R1 represent a substitute chosen from the following group B, or (C1-C10)-alkyl group optionally substituted with 1-3 substitutes chosen from halogen atom and the following group B wherein the group B represents the group consisting of phenyl group optionally substituted with phenyl group or 1-5 halogen atoms; (C3-C6)-cycloalkyl group, imidazolyl group, benzothiophenyl group, thiazolyl group optionally substituted with 1-3 (C1-C6)-alkyl groups, morpholinyl group, pyridyl group, -ORa4, -SRa4, -NRa4Ra5, -CONRa4Ra5, -SO2NRa4Ra5, -CORa6, -NRa4CORa6, -SO2Ra6, -NRa4SO2Ra6, -COORa4 and -NRa5COORa6 wherein Ra4 and Ra5 are similar or different and each represents hydrogen atom, (C1-C4)-alkyl group or phenyl group; Ra6 represents (C1-C4)-alkyl group; R2 represents hydrogen atom or (C1-C4)-alkyl group; R31 represents hydrogen atom, cyano-group, hydroxy-group, halogen atom or (C1-C4)-alkoxy-group; X represents -C-R32, and Y represents -C-R33 or nitrogen atom wherein R32 and R33 are similar or different and each represents hydrogen atom, cyano-group, halogen atom, pyrrolidinyl group, (C1-C10)-alkyl group optionally substituted with 1-3 halogen atoms, -ORa7, -SRa7, -NRa7Ra8, -NRa7CORa9, -COORa10 or -N=CH-NRa10Ra11 wherein Ra7 and Ra8 are similar or different and each represents hydrogen atom, phenyl group or (C1-C10)-alkyl group optionally substituted with (C3-C6)-cycloalkyl group or hydroxy-group; Ra9 represents (C1-C4)-alkyl group and Ra10 and Ra11 are similar or different and each represents hydrogen atom or (C1-C4)-alkyl group. Also, invention describes compound of the formula (III) given in the invention description, integrase inhibitor, antiviral agent, ant-HIV composition, anti-HIV agent, using compound of 4-oxoqionoline, method for inhibition of integrase activity, method for prophylaxis or treatment of viral infectious disease, pharmaceutical composition used for inhibition of integrase activity, antiviral composition and commercial package (variants). Invention provides the development of a pharmaceutical agent possessing inhibitory effect on activity of integrase.
EFFECT: valuable medicinal properties of compound, agent and composition.
40 cl, 7 tbl, 250 ex
Title | Year | Author | Number |
---|---|---|---|
6-(HETEROCYCLYL-SUBSTITUTED BENZYL)-4-OXOQUINOLINE DERIVATIVE AND USE THEREOF AS HIV INTEGRASE INHIBITOR | 2007 |
|
RU2399616C1 |
NOVEL COUMARIN DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | 2007 |
|
RU2428420C2 |
STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | 2005 |
|
RU2330845C1 |
TETRAHYDROCARBOLINE DERIVATIVE | 2011 |
|
RU2572818C2 |
SULFONAMIDE PERI-SUBSTITUTED BICYCLES FOR TREATMENT OF OCCLUSIVE AFFECTION OF ARTERIES | 2005 |
|
RU2403240C2 |
MODULATORS OF ATP-BINDING CARTRIDGE TRANSPORTERS | 2005 |
|
RU2528046C2 |
METHOD OF MODULATING TRANSPORTERS OF ATP-BINDING CASSETTE | 2005 |
|
RU2525115C2 |
ATP-BINDING CASETTE TRANSPORTER MODULATORS | 2005 |
|
RU2382779C2 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2711502C2 |
FLUOROQUINOLONE COMPOUNDS BASED ON PYRIDOXINE DERIVATIVES, HAVING ANTIBACTERIAL PROPERTIES | 2019 |
|
RU2713932C1 |
Authors
Dates
2006-04-27—Published
2003-11-20—Filed